Comparative Efficacy and Safety of Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Meta-Analysis
Abstract
This systematic review and meta-analysis evaluated the efficacy and safety of tegoprazan compared to proton pump inhibitors (PPIs) in the treatment of erosive esophagitis (EE). A comprehensive literature search was conducted across multiple electronic databases from inception to 25 March 2025. Randomized controlled trials comparing tegoprazan with PPIs in patients with endoscopically confirmed EE were included. Primary outcomes were healing rates and safety profiles. Four randomized controlled trials comprising 963 patients were included. Meta-analysis revealed comparable healing rates between tegoprazan and PPIs (RR: 1.03, 95% CI: 0.97-1.10), with no significant differences observed at both four weeks (RR: 1.05, 95% CI: 0.96-1.16) and eight weeks (RR: 1.01, 95% CI: 0.96-1.06). Safety analyses demonstrated similar profiles between treatments, with no significant differences in treatment-emergent adverse events (RR: 0.93, 95% CI: 0.73-1.35), drug-related adverse events (RR: 0.93, 95% CI: 0.51-1.69), or serious adverse events (RR: 1.07, 95% CI: 0.12-9.29). Symptom relief was comparable between groups across all studies, with tegoprazan showing consistent efficacy, regardless of CYP2C19 genotype. Most patients had mild to moderate EE (LA grades A and B), limiting conclusions about efficacy in severe cases. This first meta-analysis directly comparing tegoprazan with PPIs suggests that tegoprazan is an effective and safe alternative to PPIs for EE treatment. Its efficacy…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 963 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
- Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.